Another therapeutic option for increasing the sensitivity of HER2+ breast cancer by blocking BCSCs and Wnt signaling is the use of Geldanamycin, a heat shock protein-90 kDa (HSP-90) inhibitor [132]. The gene discussed is ERBB2; the disease is breast carcinoma.